



## Figures - Key Numbers

Ticker: (NASDAQ: PIRS)  
 Share price: \$3.86 (as of 11/08/18)  
 Market Cap: \$209.02M (as of 11/08/18)  
 Revenue: \$8.3M (3Q2018)  
 Net Loss: \$6.2M (3Q2018)  
 Cash and investments: \$137.3M (as of 11/07/18)

## Corporate Headquarters

Pieris Pharmaceuticals, Inc.  
 255 State Street, 9<sup>th</sup> floor  
 Boston, MA 02109  
 +1 (857) 246 8998

## Munich Site

Pieris Pharmaceuticals GmbH  
 Lise-Meitner-Strasse 30  
 85354 Freising  
 Germany  
 +49 (0) 8161 1411 400

For more information:

[info@pieris.com](mailto:info@pieris.com)

[www.pieris.com](http://www.pieris.com)

For business development or partnering inquiries, please contact our BD team: [bd@pieris.com](mailto:bd@pieris.com)

For investor relations inquiries, please contact Maria Kelman, Director of Investor Relation: [kelman@pieris.com](mailto:kelman@pieris.com)

## Company Overview


Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin®-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhaled Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics (tumor-targeted costimulatory approach and dual-checkpoint inhibitors), and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

## Pieris Strategy

- Advance its lead asthma program PRS-060 (IL4Ra) through ongoing clinical trials and strengthen its respiratory franchise for inhaled biologics
- Advance its lead IO program, PRS-343 (HER2/4-1BB), through ongoing first-in patient trials and further develop its immuno-oncology franchise
- Advance its anemia program PRS-080 (hepcidin) through ongoing Phase 2a clinical trial
- Continue to exploit its platform through new and existing partnerships

## Anticalin Proteins

Anticalin proteins are engineered lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins can bind to virtually any target of interest.



## Differentiation from Antibodies

- Formatting flexibility for multispecific drugs
- Alternative delivery routes (e.g. inhaled)
- Potential for more cost-effective prokaryotic expression
- Tunable pharmacokinetics to match biological need
- Dominant patent position and positive FTO position

## Management Team

Stephen S. Yoder, President & Chief Executive Officer  
 Louis Matis, MD, SVP & Chief Development Officer  
 Allan Reine, MD, SVP & Chief Financial Officer  
 Shane Olwill, PhD, VP, Development & Head of Immuno-Oncology  
 Christine Rothe, PhD, VP, Head of Discovery & Alliance Management  
 Mary Fitzgerald, PhD, VP, Respiratory Medicine  
 Eckhard Niemeier, VP, Business Development  
 Ahmed Mousa, VP & General Counsel  
 Ingmar Bruns, MD, PhD, VP, Clinical Development  
 Tom Bures, VP, Finance  
 Frank Vollmering - VP, Talent & Organizational Development (HR)

## Board of Directors

Ann Barbier, MD, PhD (CMO, Translate Bio)  
 Jean-Pierre Bizzari, MD (Former EVP, Celgene)  
 James Geraghty (Former Executive, Sanofi and Genzyme), Chairman  
 Christopher Kiritsy (President, Arisaph Pharmaceuticals)  
 Peter Kiener, Dphil (Former Executive, Sucampo and BMY)  
 Steven Prelack (SVP & COO, VetCor)  
 Michael Richman (CEO, NextCure)  
 Matthew Sherman (Former Executive, Acceleron Pharma)  
 Stephen S. Yoder (President & CEO, Pieris)



**February 2018:** Multi-program strategic alliance developing targeted bispecific immuno-oncology treatments for solid tumors and blood cancers



**May 2017:** Multi-program strategic co-development alliance to develop inhaled biologics for respiratory diseases. Includes PRS-060 and 4 additional programs



**January 2017:** Multi-program strategic co-development immuno-oncology alliance. Includes PRS-332 and 4 additional programs



**February 2017:** Option on anemia program PRS-080 in Japan and other Asian countries

## Pipeline Highlights

	DISCOVERY	PRECLINICAL	PHASE I	PHASE II
PRS-080				✓
PRS-343			✓	
PRS-060 (AZ)			✓	
Servier	✓	✓		
PRS-344 (Servier)	✓	✓		
PRS-300s	✓	✓		
AstraZeneca	✓			
PRS Respiratory	✓			
Seattle Genetics	✓			

## Two IO INDs Planned in 2019

### Program Highlights

#### PRS-343 – (4-1BB/HER2 Bispecific)

- Bispecific drug candidate with 4-1BB-targeting Anticalin proteins (key costimulatory target for tumor-specific T cells) and a HER2-targeting antibody (validated expression in bladder, gastric, breast cancer and others)
- PRS-343 has demonstrated strong tumor growth inhibition and lymphocyte infiltration *in vivo*, while avoiding undesirable peripheral T-cell activation
- Currently in Phase 1 clinical trial
- Initiated combination trial with atezolizumab and PRS-343 in H2 2018

#### PRS-344 – (4-1BB/PD-L1 Bispecific)

- Bispecific drug candidate with a 4-1BB-targeting Anticalin proteins (enhancing mitochondrial function in T cells) and a PD-L1-targeting antibody, a target combination that has demonstrated robust preclinical anti-tumor activity
- PRS-344 is being co-developed with Servier; Pieris can opt-in for U.S. commercial rights

#### PRS-332 – (PD-1 / undisclosed checkpoint)

- Bispecific program combining an Anticalin candidate against an undisclosed key checkpoint target with a PD-1-targeting antibody
- PRS-332 is being co-developed with Servier; Pieris retains U.S. commercial rights

#### Pieris Immuno-Oncology Strategy

- Engage immune costimulatory or checkpoint targets in a highly novel, targeted manner with unique multispecifics
- Simultaneously block multiple immune checkpoints in one drug built on key backbone components (e.g. PD-L1)

#### PRS-060 – IL-4R $\alpha$ Antagonist

- Lead respiratory program targeting IL-4R $\alpha$  for asthma
- Differentiated from injectable antibodies against IL-4 and IL-13 through inhaled delivery directly to the lungs
- Local delivery is more convenient for patients and may allow for lower doses, potentially resulting in a significant cost of goods advantage and expanded patient population over systemic antibodies
- PRS-060 is being developed in a collaboration with AstraZeneca
- Started Phase 1 clinical trial in 2017

#### PRS-080 – Anemia

- Non-core program against hepcidin
- Targets anemia in CKD and cancer
- Phase 1b trial in CKD hemodialysis (HD) patients completed successfully
- Phase 2a trial in CKD HD patients ongoing
- ASKA Pharmaceutical with option for Japan

